Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis

Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis

Classical Hodgkin lymphoma (HL) patients presenting a relapsed/refractory (R/R) disease are currently managed with salvage chemotherapy followed by autologous stem cell transplantation (ASCT). However, almost 25–30% of these patients fail to achieve a complete response (CR) with standard salvage reg...

Full description

Bibliographic Details
Main Authors: Fulvio Massaro, Nathalie Meuleman, Dominique Bron, Marie Vercruyssen, Marie Maerevoet
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Cancers
Subjects:
Hodgkin lymphoma
antibody-drug conjugate
immune checkpoint inhibition
brentuximab vedotin
pembrolizumab
salvage therapy
Online Access:https://www.mdpi.com/2072-6694/14/4/982

Similar Items

Similar Items